Conceptual Entity – Page 4

AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition

WuXi AppTec and WuXi Biologics Consider Asset Sales Amid BIOSECURE Act Scrutiny

9 months ago talkbio0Tagged AppTec, asset, Biological Factors, BIOSECURE, Industry, Relations, Sales - occupational activity, U.S.-China, WuXi

WuXi AppTec, WuXi Biologics, BIOSECURE Act, asset sales, biotech industry, US-China relations

Illumina Introduces MiSeq i100 Series: Simplifying Next-Generation Sequencing with Push-Button Workflows

10 months ago talkbio0Tagged Benchtop DNA Sequencer, DNA Sequence, Genomics, High-Throughput Nucleotide Sequencing, Illumina, MiSeq, Push-Button, Workflow

Illumina, MiSeq i100 Series, Benchtop DNA Sequencer, Push-Button Workflows, Next-Generation Sequencing (NGS), Genomics, DNA Sequencing

Biogen’s Higher Dose Spinraza Shows Enhanced Efficacy in Treating Spinal Muscular Atrophy

10 months ago talkbio0Tagged Biogen, Clinical Trials, DEVOTE, Dose Regimen, High, Improvement, Motor function (observable entity), Nerve Degeneration, nusinersen, Spinal Muscular Atrophy, Spinraza

Biogen, Spinraza, Nusinersen, Spinal Muscular Atrophy (SMA), Higher Dose Regimen, Clinical Trial Results, DEVOTE Study, Motor Function Improvement, Neurodegeneration Reduction

Scholar Rock’s Apitegromab Shows Significant Improvement in Spinal Muscular Atrophy Treatment

10 months ago talkbio0Tagged apitegromab, Clinical Trials, GDF8 protein, human, Improvement, Motor function (observable entity), Phase 3, Psychological inhibition, Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA), Apitegromab, Phase 3 Clinical Trial, Motor Function Improvement, Myostatin Inhibition

FDA Issues Warning on Rare Liver Injury Risk with Veozah (Fezolinetant) for Menopausal Hot Flashes

11 months ago talkbio0Tagged Cautionary Warning, fezolinetant, Injury of liver, Menopause, Neurokinin 3, nonhormonal prescription medicine, United States Food and Drug Administration, Veozah

Veozah (fezolinetant), FDA warning, Liver injury, Menopausal hot flashes, Nonhormonal prescription medicine, Neurokinin 3 (NK3) receptor antagonists

Milestone’s Etripamil Nasal Spray Advances Towards Regulatory Filing in China for PSVT Treatment

11 months ago talkbio0Tagged Cardiovascular system, China, etripamil nasal spray, Milestone, Paroxysmal, Paroxysmal supraventricular tachycardia, Pharmaceuticals Ltd, Regulatory Filing, Tenascin, human

Etripamil nasal spray, Paroxysmal supraventricular tachycardia (PSVT), Milestone Pharmaceuticals, Ji Xing Pharmaceuticals Ltd, China regulatory filing, Cardiovascular therapies